Clinical results after high-dose intensity-modulated radiotherapy for high-risk prostate cancer

Purpose: Patients with high-risk prostate cancer (PC) can be treated with high-dose intensity-modulated radiotherapy (IMRT) and long-term androgen deprivation (AD). In this paper we report on (i) late toxicity and (ii) biochemical (bRFS) and clinical relapse-free survival (cRFS) of this combined treatment.

Methods: 126 patients with high-risk PC (T3-4 or PSA >20 ng/mL or Gleason 8-10) and ≥24 months of followup were treated with high-dose IMRT and AD. Late toxicity was recorded. Biochemical relapse was defined as PSA nadir +2 ng/mL. Clinical relapse was defined as local failure or metastases.

Results: The incidence of late grade 3 gastrointestinal and genitourinary toxicity was 2 and 6%, respectively. Five-year bRFS and cRFS were 73% and 86% respectively. AD was a significant predictor of bRFS (P = 0.001) and cRFS (P = 0.01).

Conclusion: High-dose IMRT and AD for high-risk PC offers excellent biochemical and clinical control with low toxicity.

Writtenby:
Fonteyne V, Lumen N, Villeirs G, Ost P, De Meerleer G. Are you the author?
Department of Radiotherapy, Ghent University Hospital, 9000 Ghent, Belgium.

Reference: Adv Urol. 2012;2012:368528.
doi: 10.1155/2012/368528

PubMed Abstract
PMID: 22190918

UroToday.com Prostate Cancer Section

Login